| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.15 | 0.003 |